Kathryn Colborn
Concepts (440)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Electronic Health Records | 11 | 2025 | 1090 | 2.600 |
Why?
| | Postoperative Complications | 30 | 2025 | 2716 | 2.180 |
Why?
| | Shock, Septic | 5 | 2025 | 209 | 1.340 |
Why?
| | Sepsis | 6 | 2023 | 611 | 1.230 |
Why?
| | Quality Improvement | 14 | 2023 | 1215 | 1.210 |
Why?
| | Machine Learning | 9 | 2026 | 516 | 1.190 |
Why?
| | Urinary Tract Infections | 3 | 2022 | 193 | 1.190 |
Why?
| | Surgical Procedures, Operative | 5 | 2023 | 266 | 1.180 |
Why?
| | Surgical Wound Infection | 7 | 2025 | 313 | 1.170 |
Why?
| | Pancreatic Neoplasms | 10 | 2024 | 859 | 1.140 |
Why?
| | Malaria | 4 | 2023 | 64 | 1.050 |
Why?
| | Retrospective Studies | 47 | 2025 | 15901 | 0.780 |
Why?
| | Postoperative Hemorrhage | 2 | 2023 | 88 | 0.770 |
Why?
| | Models, Statistical | 4 | 2020 | 665 | 0.760 |
Why?
| | Humans | 128 | 2026 | 138972 | 0.750 |
Why?
| | Malaria, Falciparum | 2 | 2018 | 27 | 0.740 |
Why?
| | Databases, Factual | 15 | 2025 | 1409 | 0.730 |
Why?
| | Pain | 2 | 2023 | 779 | 0.670 |
Why?
| | Plasmodium vivax | 2 | 2018 | 4 | 0.670 |
Why?
| | Malaria, Vivax | 2 | 2018 | 4 | 0.670 |
Why?
| | Adenocarcinoma | 5 | 2024 | 882 | 0.640 |
Why?
| | Patient Reported Outcome Measures | 7 | 2024 | 416 | 0.620 |
Why?
| | Artificial Intelligence | 1 | 2023 | 293 | 0.610 |
Why?
| | Palliative Care | 8 | 2025 | 815 | 0.590 |
Why?
| | Pneumonia | 3 | 2023 | 644 | 0.590 |
Why?
| | Risk Assessment | 17 | 2024 | 3466 | 0.590 |
Why?
| | Breast Neoplasms | 7 | 2024 | 2283 | 0.580 |
Why?
| | Surgeons | 4 | 2025 | 327 | 0.580 |
Why?
| | Inpatients | 4 | 2023 | 505 | 0.570 |
Why?
| | Plasmodium falciparum | 1 | 2018 | 30 | 0.550 |
Why?
| | Poisson Distribution | 1 | 2018 | 77 | 0.550 |
Why?
| | Thoracic Surgery | 3 | 2025 | 139 | 0.550 |
Why?
| | Health Plan Implementation | 1 | 2019 | 145 | 0.540 |
Why?
| | Neoadjuvant Therapy | 8 | 2024 | 408 | 0.540 |
Why?
| | Risk Factors | 25 | 2025 | 10385 | 0.510 |
Why?
| | Mosquito Control | 2 | 2023 | 28 | 0.510 |
Why?
| | Middle Aged | 40 | 2025 | 33782 | 0.510 |
Why?
| | Hospitalization | 6 | 2021 | 2228 | 0.490 |
Why?
| | Female | 58 | 2026 | 74016 | 0.480 |
Why?
| | Aged | 32 | 2025 | 24172 | 0.470 |
Why?
| | Mosquito Nets | 1 | 2015 | 2 | 0.470 |
Why?
| | Quality of Life | 11 | 2025 | 2962 | 0.470 |
Why?
| | Anopheles | 1 | 2015 | 16 | 0.460 |
Why?
| | Carcinoma, Pancreatic Ductal | 3 | 2023 | 267 | 0.460 |
Why?
| | Male | 51 | 2026 | 68250 | 0.440 |
Why?
| | Drug Prescriptions | 3 | 2021 | 260 | 0.430 |
Why?
| | Extracorporeal Membrane Oxygenation | 3 | 2023 | 335 | 0.430 |
Why?
| | Adult | 36 | 2025 | 38393 | 0.420 |
Why?
| | Thoracic Surgical Procedures | 2 | 2025 | 87 | 0.400 |
Why?
| | Mastectomy, Segmental | 2 | 2024 | 97 | 0.380 |
Why?
| | Patient Discharge | 2 | 2020 | 915 | 0.380 |
Why?
| | Ambulatory Surgical Procedures | 2 | 2023 | 73 | 0.380 |
Why?
| | Primary Health Care | 3 | 2025 | 1776 | 0.370 |
Why?
| | Hospital Mortality | 1 | 2016 | 920 | 0.370 |
Why?
| | Decision Support Systems, Clinical | 2 | 2026 | 242 | 0.360 |
Why?
| | Robotic Surgical Procedures | 2 | 2024 | 143 | 0.360 |
Why?
| | Hospice and Palliative Care Nursing | 2 | 2023 | 87 | 0.350 |
Why?
| | Preoperative Care | 3 | 2024 | 366 | 0.350 |
Why?
| | Child, Preschool | 16 | 2026 | 11158 | 0.350 |
Why?
| | Algorithms | 4 | 2019 | 1730 | 0.350 |
Why?
| | Mastectomy | 4 | 2024 | 148 | 0.340 |
Why?
| | Influenza, Human | 3 | 2021 | 614 | 0.320 |
Why?
| | Incidence | 8 | 2023 | 2830 | 0.320 |
Why?
| | Opioid-Related Disorders | 1 | 2018 | 546 | 0.320 |
Why?
| | Heart Failure | 5 | 2025 | 2065 | 0.320 |
Why?
| | Hospitals | 4 | 2025 | 699 | 0.310 |
Why?
| | Emergency Service, Hospital | 4 | 2025 | 2114 | 0.310 |
Why?
| | Zebrafish | 2 | 2025 | 496 | 0.310 |
Why?
| | Emergency Treatment | 2 | 2021 | 124 | 0.310 |
Why?
| | Colorado | 9 | 2025 | 4543 | 0.300 |
Why?
| | United States | 19 | 2025 | 15074 | 0.280 |
Why?
| | Cohort Studies | 11 | 2024 | 5744 | 0.280 |
Why?
| | Osteoarthritis, Knee | 2 | 2021 | 256 | 0.270 |
Why?
| | Research Design | 3 | 2022 | 1120 | 0.270 |
Why?
| | Aged, 80 and over | 10 | 2024 | 7685 | 0.270 |
Why?
| | Pancreatectomy | 3 | 2024 | 244 | 0.270 |
Why?
| | Logistic Models | 5 | 2023 | 2093 | 0.270 |
Why?
| | Patient Satisfaction | 4 | 2024 | 689 | 0.260 |
Why?
| | Cardiac Surgical Procedures | 2 | 2023 | 576 | 0.260 |
Why?
| | Seasons | 3 | 2025 | 538 | 0.260 |
Why?
| | Chagas Disease | 2 | 2018 | 44 | 0.260 |
Why?
| | Prognosis | 10 | 2024 | 3995 | 0.260 |
Why?
| | Autism Spectrum Disorder | 2 | 2023 | 403 | 0.250 |
Why?
| | Rectal Neoplasms | 2 | 2019 | 143 | 0.250 |
Why?
| | Mass Drug Administration | 3 | 2023 | 7 | 0.250 |
Why?
| | Asthma | 1 | 2019 | 1893 | 0.250 |
Why?
| | Arthroplasty, Replacement, Knee | 2 | 2021 | 366 | 0.240 |
Why?
| | Time-to-Treatment | 2 | 2025 | 213 | 0.240 |
Why?
| | Infant | 12 | 2026 | 9577 | 0.230 |
Why?
| | Intracranial Pressure | 1 | 2026 | 60 | 0.230 |
Why?
| | Chemotherapy, Adjuvant | 5 | 2024 | 374 | 0.230 |
Why?
| | Elective Surgical Procedures | 2 | 2024 | 192 | 0.230 |
Why?
| | Craniofacial Abnormalities | 1 | 2025 | 74 | 0.230 |
Why?
| | CA-19-9 Antigen | 1 | 2024 | 27 | 0.220 |
Why?
| | Treatment Outcome | 13 | 2025 | 10921 | 0.220 |
Why?
| | Varicose Veins | 1 | 2024 | 16 | 0.210 |
Why?
| | Adolescent | 15 | 2026 | 21581 | 0.210 |
Why?
| | Heart Defects, Congenital | 2 | 2022 | 850 | 0.210 |
Why?
| | Zebrafish Proteins | 2 | 2025 | 287 | 0.200 |
Why?
| | Hypothermia | 1 | 2023 | 39 | 0.200 |
Why?
| | Specialties, Surgical | 2 | 2021 | 76 | 0.200 |
Why?
| | Metastasectomy | 1 | 2023 | 20 | 0.200 |
Why?
| | Hernia, Hiatal | 1 | 2023 | 39 | 0.200 |
Why?
| | Endarterectomy, Carotid | 1 | 2023 | 54 | 0.200 |
Why?
| | Predictive Value of Tests | 4 | 2022 | 2030 | 0.200 |
Why?
| | Multivariate Analysis | 2 | 2023 | 1497 | 0.200 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2023 | 34 | 0.200 |
Why?
| | Analgesics, Opioid | 3 | 2021 | 1092 | 0.190 |
Why?
| | Insecticides | 1 | 2023 | 42 | 0.190 |
Why?
| | MEF2 Transcription Factors | 1 | 2022 | 59 | 0.190 |
Why?
| | Risk Adjustment | 1 | 2023 | 81 | 0.190 |
Why?
| | Young Adult | 11 | 2020 | 13371 | 0.190 |
Why?
| | Europe | 1 | 2023 | 407 | 0.190 |
Why?
| | Ischemic Attack, Transient | 1 | 2023 | 67 | 0.190 |
Why?
| | Practice Patterns, Physicians' | 3 | 2021 | 1321 | 0.190 |
Why?
| | Nervous System Diseases | 1 | 2025 | 273 | 0.190 |
Why?
| | Sentinel Lymph Node | 1 | 2022 | 45 | 0.190 |
Why?
| | Telemetry | 1 | 2022 | 40 | 0.190 |
Why?
| | Microcephaly | 1 | 2023 | 99 | 0.190 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2023 | 75 | 0.190 |
Why?
| | Medication Therapy Management | 1 | 2023 | 77 | 0.190 |
Why?
| | Carotid Stenosis | 1 | 2023 | 96 | 0.190 |
Why?
| | Polypharmacy | 1 | 2023 | 88 | 0.190 |
Why?
| | Syncope | 1 | 2022 | 55 | 0.190 |
Why?
| | Galectins | 1 | 2022 | 24 | 0.180 |
Why?
| | Pneumonectomy | 1 | 2023 | 156 | 0.180 |
Why?
| | Information Dissemination | 1 | 2024 | 223 | 0.180 |
Why?
| | Chemoradiotherapy, Adjuvant | 2 | 2019 | 43 | 0.180 |
Why?
| | Drug Hypersensitivity | 1 | 2023 | 95 | 0.180 |
Why?
| | Ivermectin | 1 | 2021 | 14 | 0.180 |
Why?
| | Mozambique | 2 | 2018 | 7 | 0.180 |
Why?
| | Delirium | 1 | 2023 | 97 | 0.180 |
Why?
| | Neuroendocrine Tumors | 1 | 2023 | 108 | 0.180 |
Why?
| | Pain, Postoperative | 2 | 2021 | 309 | 0.170 |
Why?
| | Program Evaluation | 3 | 2021 | 917 | 0.170 |
Why?
| | Ambulatory Care | 1 | 2025 | 575 | 0.170 |
Why?
| | Oxycodone | 1 | 2021 | 48 | 0.170 |
Why?
| | Vascular Surgical Procedures | 1 | 2024 | 325 | 0.170 |
Why?
| | Dysbiosis | 1 | 2022 | 180 | 0.170 |
Why?
| | Child | 13 | 2026 | 21936 | 0.170 |
Why?
| | Communication | 2 | 2025 | 932 | 0.170 |
Why?
| | New Guinea | 2 | 2018 | 4 | 0.170 |
Why?
| | Knee Joint | 2 | 2021 | 407 | 0.170 |
Why?
| | Surgery Department, Hospital | 1 | 2020 | 22 | 0.170 |
Why?
| | Gastric Bypass | 1 | 2022 | 118 | 0.170 |
Why?
| | Brain Injuries, Traumatic | 1 | 2026 | 380 | 0.160 |
Why?
| | Arthroplasty | 1 | 2020 | 52 | 0.160 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2024 | 1742 | 0.160 |
Why?
| | Hypersensitivity | 1 | 2023 | 254 | 0.160 |
Why?
| | Anti-Anxiety Agents | 1 | 2010 | 43 | 0.160 |
Why?
| | Faculty | 1 | 2021 | 150 | 0.160 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2022 | 239 | 0.160 |
Why?
| | Terminal Care | 1 | 2023 | 249 | 0.160 |
Why?
| | Artemisinins | 1 | 2019 | 3 | 0.160 |
Why?
| | Phenotype | 2 | 2025 | 3143 | 0.160 |
Why?
| | Antimalarials | 1 | 2019 | 32 | 0.150 |
Why?
| | Radiotherapy, Intensity-Modulated | 2 | 2019 | 137 | 0.150 |
Why?
| | Latent Tuberculosis | 1 | 2010 | 68 | 0.150 |
Why?
| | Anti-Infective Agents | 1 | 2022 | 239 | 0.150 |
Why?
| | Waiting Lists | 2 | 2021 | 242 | 0.150 |
Why?
| | Intensive Care Units | 2 | 2022 | 871 | 0.150 |
Why?
| | Prisons | 1 | 2010 | 82 | 0.150 |
Why?
| | Laparoscopy | 1 | 2023 | 452 | 0.150 |
Why?
| | Induction Chemotherapy | 1 | 2019 | 78 | 0.150 |
Why?
| | General Surgery | 1 | 2021 | 175 | 0.150 |
Why?
| | Healthcare Disparities | 3 | 2025 | 662 | 0.150 |
Why?
| | Organ Transplantation | 1 | 2021 | 242 | 0.150 |
Why?
| | Education, Medical, Undergraduate | 1 | 2021 | 189 | 0.150 |
Why?
| | Defibrillators, Implantable | 1 | 2022 | 305 | 0.150 |
Why?
| | Aftercare | 1 | 2020 | 215 | 0.150 |
Why?
| | Patient Acceptance of Health Care | 1 | 2025 | 856 | 0.150 |
Why?
| | Prospective Studies | 7 | 2026 | 7661 | 0.150 |
Why?
| | Vaccination | 2 | 2025 | 1438 | 0.150 |
Why?
| | Venous Thromboembolism | 1 | 2023 | 324 | 0.140 |
Why?
| | Rural Population | 2 | 2020 | 582 | 0.140 |
Why?
| | Datasets as Topic | 1 | 2019 | 125 | 0.140 |
Why?
| | Social Marketing | 1 | 2008 | 16 | 0.140 |
Why?
| | Practice Guidelines as Topic | 2 | 2024 | 1569 | 0.140 |
Why?
| | Quinolines | 1 | 2019 | 150 | 0.140 |
Why?
| | Soft Tissue Infections | 1 | 2008 | 39 | 0.140 |
Why?
| | Outpatients | 1 | 2022 | 419 | 0.140 |
Why?
| | Hospitals, University | 1 | 2018 | 175 | 0.140 |
Why?
| | Ventricular Function | 1 | 2018 | 57 | 0.140 |
Why?
| | Developed Countries | 1 | 2018 | 39 | 0.140 |
Why?
| | Triage | 1 | 2021 | 241 | 0.140 |
Why?
| | Cognition | 2 | 2023 | 1179 | 0.140 |
Why?
| | Reproductive Medicine | 1 | 2008 | 14 | 0.140 |
Why?
| | Community Participation | 1 | 2019 | 133 | 0.140 |
Why?
| | Obesity, Morbid | 1 | 2022 | 271 | 0.140 |
Why?
| | Computers, Handheld | 1 | 2018 | 25 | 0.140 |
Why?
| | Herpesvirus 4, Human | 1 | 2019 | 165 | 0.140 |
Why?
| | Autistic Disorder | 1 | 2020 | 206 | 0.140 |
Why?
| | Climate | 1 | 2018 | 86 | 0.140 |
Why?
| | Population Groups | 1 | 2018 | 59 | 0.140 |
Why?
| | Burns | 1 | 2022 | 340 | 0.140 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2022 | 448 | 0.140 |
Why?
| | ROC Curve | 1 | 2019 | 564 | 0.140 |
Why?
| | Patient Admission | 1 | 2019 | 202 | 0.140 |
Why?
| | Geography | 1 | 2018 | 200 | 0.140 |
Why?
| | Condoms | 1 | 2008 | 102 | 0.140 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2019 | 98 | 0.140 |
Why?
| | Sentinel Surveillance | 1 | 2017 | 48 | 0.140 |
Why?
| | Sentinel Lymph Node Biopsy | 3 | 2023 | 113 | 0.140 |
Why?
| | Immunoglobulin A | 1 | 2019 | 214 | 0.130 |
Why?
| | Safety-net Providers | 1 | 2019 | 118 | 0.130 |
Why?
| | Recovery of Function | 1 | 2021 | 665 | 0.130 |
Why?
| | Substance Abuse, Intravenous | 1 | 2008 | 117 | 0.130 |
Why?
| | Occupational Health | 1 | 2010 | 206 | 0.130 |
Why?
| | Lymph Node Excision | 3 | 2023 | 168 | 0.130 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2010 | 358 | 0.130 |
Why?
| | Patient Compliance | 1 | 2021 | 602 | 0.130 |
Why?
| | Epidemics | 1 | 2018 | 91 | 0.130 |
Why?
| | Gastroenteritis | 1 | 2017 | 68 | 0.130 |
Why?
| | Cell Phone | 1 | 2017 | 76 | 0.130 |
Why?
| | Qualitative Research | 1 | 2024 | 1448 | 0.130 |
Why?
| | Anxiety Disorders | 1 | 2010 | 376 | 0.130 |
Why?
| | Students, Medical | 1 | 2021 | 354 | 0.130 |
Why?
| | Influenza Vaccines | 1 | 2021 | 536 | 0.120 |
Why?
| | Radiotherapy, Conformal | 1 | 2016 | 73 | 0.120 |
Why?
| | Telemedicine | 1 | 2025 | 876 | 0.120 |
Why?
| | Occupational Exposure | 1 | 2010 | 340 | 0.120 |
Why?
| | Membrane Glycoproteins | 1 | 2019 | 501 | 0.120 |
Why?
| | Patient Protection and Affordable Care Act | 1 | 2017 | 102 | 0.120 |
Why?
| | Fever | 1 | 2017 | 305 | 0.120 |
Why?
| | Patient Readmission | 2 | 2020 | 703 | 0.120 |
Why?
| | Forecasting | 1 | 2018 | 384 | 0.120 |
Why?
| | Parents | 1 | 2025 | 1423 | 0.120 |
Why?
| | Alcoholism | 1 | 2023 | 818 | 0.120 |
Why?
| | Nurse Practitioners | 1 | 2018 | 137 | 0.120 |
Why?
| | Follow-Up Studies | 5 | 2024 | 5152 | 0.120 |
Why?
| | Melanoma | 1 | 2022 | 757 | 0.120 |
Why?
| | Models, Organizational | 1 | 2016 | 147 | 0.120 |
Why?
| | Morbidity | 3 | 2022 | 321 | 0.120 |
Why?
| | Atrial Fibrillation | 1 | 2020 | 377 | 0.120 |
Why?
| | Skin Neoplasms | 1 | 2022 | 837 | 0.120 |
Why?
| | Humidity | 1 | 2015 | 46 | 0.110 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2023 | 849 | 0.110 |
Why?
| | Mobile Applications | 1 | 2017 | 178 | 0.110 |
Why?
| | Mass Screening | 2 | 2020 | 1296 | 0.110 |
Why?
| | Diarrhea | 3 | 2023 | 182 | 0.110 |
Why?
| | Antibodies, Viral | 1 | 2019 | 649 | 0.110 |
Why?
| | Advance Care Planning | 1 | 2018 | 222 | 0.110 |
Why?
| | Massage | 2 | 2010 | 42 | 0.110 |
Why?
| | Anticonvulsants | 1 | 2016 | 219 | 0.110 |
Why?
| | Cannabidiol | 1 | 2016 | 123 | 0.110 |
Why?
| | Stroke | 1 | 2023 | 1140 | 0.110 |
Why?
| | Time Factors | 5 | 2024 | 6869 | 0.110 |
Why?
| | Survival Rate | 3 | 2024 | 1934 | 0.110 |
Why?
| | Emergency Medical Services | 1 | 2021 | 635 | 0.110 |
Why?
| | Models, Biological | 1 | 2021 | 1810 | 0.110 |
Why?
| | Sensitivity and Specificity | 1 | 2018 | 1939 | 0.100 |
Why?
| | Family Practice | 1 | 2018 | 463 | 0.100 |
Why?
| | Parasitemia | 1 | 2013 | 13 | 0.100 |
Why?
| | Chronic Pain | 1 | 2018 | 272 | 0.100 |
Why?
| | Environmental Exposure | 1 | 2018 | 569 | 0.100 |
Why?
| | Indians, North American | 1 | 2009 | 645 | 0.100 |
Why?
| | Research | 1 | 2016 | 451 | 0.100 |
Why?
| | Myocardial Infarction | 1 | 2020 | 1063 | 0.100 |
Why?
| | Software | 1 | 2018 | 670 | 0.100 |
Why?
| | Longitudinal Studies | 3 | 2024 | 2850 | 0.100 |
Why?
| | Medicaid | 1 | 2017 | 449 | 0.100 |
Why?
| | Epilepsy | 1 | 2016 | 335 | 0.090 |
Why?
| | Heart-Assist Devices | 1 | 2018 | 556 | 0.090 |
Why?
| | Diagnostic Tests, Routine | 2 | 2024 | 109 | 0.090 |
Why?
| | Axilla | 2 | 2023 | 48 | 0.090 |
Why?
| | Temperature | 1 | 2015 | 660 | 0.090 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2023 | 1522 | 0.090 |
Why?
| | Multicenter Studies as Topic | 2 | 2023 | 321 | 0.090 |
Why?
| | Feedback | 2 | 2023 | 174 | 0.090 |
Why?
| | Emergencies | 2 | 2025 | 178 | 0.090 |
Why?
| | Washington | 2 | 2025 | 159 | 0.090 |
Why?
| | Patients | 2 | 2023 | 180 | 0.090 |
Why?
| | Prevalence | 3 | 2023 | 2745 | 0.090 |
Why?
| | Uganda | 2 | 2023 | 85 | 0.090 |
Why?
| | Age Factors | 4 | 2021 | 3276 | 0.090 |
Why?
| | Pain Management | 2 | 2010 | 389 | 0.090 |
Why?
| | Disease Progression | 1 | 2019 | 2752 | 0.090 |
Why?
| | Lymphatic Metastasis | 2 | 2023 | 323 | 0.080 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2849 | 0.080 |
Why?
| | Internship and Residency | 1 | 2021 | 1183 | 0.080 |
Why?
| | Heart Transplantation | 1 | 2017 | 707 | 0.080 |
Why?
| | Laboratories | 2 | 2021 | 107 | 0.080 |
Why?
| | Antineoplastic Agents | 1 | 2021 | 2152 | 0.080 |
Why?
| | Lung Neoplasms | 1 | 2023 | 2533 | 0.080 |
Why?
| | Postoperative Period | 2 | 2021 | 355 | 0.080 |
Why?
| | Guatemala | 2 | 2023 | 327 | 0.080 |
Why?
| | Anti-HIV Agents | 1 | 2016 | 836 | 0.080 |
Why?
| | Societies, Medical | 2 | 2024 | 835 | 0.080 |
Why?
| | Lymph Nodes | 2 | 2023 | 492 | 0.080 |
Why?
| | Pandemics | 3 | 2023 | 1645 | 0.080 |
Why?
| | Feeding Behavior | 1 | 2015 | 685 | 0.080 |
Why?
| | Delivery of Health Care | 1 | 2016 | 963 | 0.080 |
Why?
| | Anti-Bacterial Agents | 3 | 2025 | 1811 | 0.070 |
Why?
| | Biomedical Research | 2 | 2025 | 695 | 0.070 |
Why?
| | Surveys and Questionnaires | 4 | 2023 | 5884 | 0.070 |
Why?
| | Guideline Adherence | 2 | 2024 | 560 | 0.070 |
Why?
| | Proportional Hazards Models | 2 | 2023 | 1281 | 0.070 |
Why?
| | Echocardiography | 2 | 2022 | 638 | 0.070 |
Why?
| | Comorbidity | 2 | 2022 | 1657 | 0.070 |
Why?
| | Immunization Programs | 1 | 2009 | 220 | 0.060 |
Why?
| | Referral and Consultation | 2 | 2023 | 795 | 0.060 |
Why?
| | Urban Population | 2 | 2020 | 485 | 0.060 |
Why?
| | School Health Services | 1 | 2009 | 231 | 0.060 |
Why?
| | Length of Stay | 2 | 2023 | 1237 | 0.060 |
Why?
| | Insurance Coverage | 2 | 2017 | 235 | 0.060 |
Why?
| | Affect | 1 | 2008 | 313 | 0.060 |
Why?
| | Nebraska | 1 | 2025 | 19 | 0.060 |
Why?
| | Wyoming | 1 | 2025 | 27 | 0.060 |
Why?
| | Pilot Projects | 2 | 2023 | 1765 | 0.060 |
Why?
| | Glasgow Coma Scale | 1 | 2026 | 200 | 0.060 |
Why?
| | Infant, Newborn | 3 | 2022 | 6158 | 0.050 |
Why?
| | Cross-Sectional Studies | 3 | 2023 | 5530 | 0.050 |
Why?
| | Cytokines | 2 | 2023 | 2083 | 0.050 |
Why?
| | Acute Disease | 2 | 2017 | 993 | 0.050 |
Why?
| | Socioeconomic Factors | 2 | 2020 | 1312 | 0.050 |
Why?
| | Body Mass Index | 2 | 2023 | 2390 | 0.050 |
Why?
| | Animals | 4 | 2025 | 37243 | 0.050 |
Why?
| | Monitoring, Physiologic | 1 | 2026 | 280 | 0.050 |
Why?
| | Health Care Surveys | 2 | 2010 | 567 | 0.050 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2024 | 214 | 0.050 |
Why?
| | Motivational Interviewing | 1 | 2025 | 115 | 0.050 |
Why?
| | Multilocus Sequence Typing | 1 | 2022 | 16 | 0.050 |
Why?
| | Community Health Workers | 1 | 2023 | 62 | 0.050 |
Why?
| | Herniorrhaphy | 1 | 2023 | 70 | 0.050 |
Why?
| | Health Facilities | 1 | 2023 | 86 | 0.050 |
Why?
| | Growth Disorders | 1 | 2023 | 85 | 0.050 |
Why?
| | Sternotomy | 1 | 2022 | 26 | 0.050 |
Why?
| | Cardiology | 1 | 2025 | 279 | 0.050 |
Why?
| | Biological Variation, Population | 1 | 2022 | 20 | 0.050 |
Why?
| | Death | 1 | 2023 | 125 | 0.050 |
Why?
| | Body Surface Area | 1 | 2022 | 35 | 0.050 |
Why?
| | Papua New Guinea | 1 | 2012 | 9 | 0.050 |
Why?
| | Vomiting | 1 | 2023 | 129 | 0.050 |
Why?
| | Stroke Volume | 1 | 2025 | 584 | 0.050 |
Why?
| | Breast | 1 | 2023 | 158 | 0.050 |
Why?
| | Burn Units | 1 | 2022 | 48 | 0.050 |
Why?
| | Alleles | 1 | 2025 | 890 | 0.050 |
Why?
| | Cough | 1 | 2023 | 125 | 0.050 |
Why?
| | Carotid Arteries | 1 | 2023 | 195 | 0.050 |
Why?
| | Patient Acuity | 1 | 2022 | 47 | 0.050 |
Why?
| | Neutrophil Infiltration | 1 | 2022 | 108 | 0.040 |
Why?
| | HIV Infections | 1 | 2016 | 2945 | 0.040 |
Why?
| | Disease-Free Survival | 1 | 2023 | 704 | 0.040 |
Why?
| | Survival Analysis | 1 | 2024 | 1311 | 0.040 |
Why?
| | Inappropriate Prescribing | 1 | 2022 | 57 | 0.040 |
Why?
| | Demography | 1 | 2022 | 298 | 0.040 |
Why?
| | Educational Status | 1 | 2023 | 475 | 0.040 |
Why?
| | Neurosurgical Procedures | 1 | 2023 | 204 | 0.040 |
Why?
| | Sample Size | 1 | 2021 | 127 | 0.040 |
Why?
| | Gastrectomy | 1 | 2022 | 132 | 0.040 |
Why?
| | Receptor, ErbB-2 | 1 | 2023 | 349 | 0.040 |
Why?
| | Ligands | 1 | 2023 | 666 | 0.040 |
Why?
| | Preoperative Period | 1 | 2021 | 141 | 0.040 |
Why?
| | Habits | 1 | 2020 | 51 | 0.040 |
Why?
| | Chemoradiotherapy | 1 | 2022 | 229 | 0.040 |
Why?
| | Focus Groups | 1 | 2023 | 538 | 0.040 |
Why?
| | Research Personnel | 1 | 2022 | 183 | 0.040 |
Why?
| | Lung | 2 | 2024 | 4103 | 0.040 |
Why?
| | Censuses | 1 | 2020 | 37 | 0.040 |
Why?
| | Schools, Medical | 1 | 2021 | 151 | 0.040 |
Why?
| | South Africa | 1 | 2021 | 229 | 0.040 |
Why?
| | Reoperation | 1 | 2023 | 579 | 0.040 |
Why?
| | Fear | 1 | 2023 | 344 | 0.040 |
Why?
| | Policy | 1 | 2021 | 149 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2023 | 1235 | 0.040 |
Why?
| | Blood Proteins | 1 | 2022 | 244 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2021 | 517 | 0.040 |
Why?
| | Early Diagnosis | 1 | 2020 | 240 | 0.040 |
Why?
| | Influenza A Virus, H3N2 Subtype | 1 | 2019 | 46 | 0.040 |
Why?
| | Urination Disorders | 1 | 2019 | 14 | 0.040 |
Why?
| | Epstein-Barr Virus Nuclear Antigens | 1 | 2019 | 12 | 0.040 |
Why?
| | Organoplatinum Compounds | 1 | 2019 | 48 | 0.040 |
Why?
| | Risk | 1 | 2022 | 913 | 0.040 |
Why?
| | Neoplasm Staging | 1 | 2023 | 1370 | 0.040 |
Why?
| | Program Development | 1 | 2021 | 362 | 0.040 |
Why?
| | Mentors | 1 | 2021 | 209 | 0.040 |
Why?
| | Leucovorin | 1 | 2019 | 85 | 0.040 |
Why?
| | Chi-Square Distribution | 1 | 2010 | 522 | 0.040 |
Why?
| | Inflammation Mediators | 1 | 2022 | 513 | 0.040 |
Why?
| | Kenya | 1 | 2019 | 122 | 0.040 |
Why?
| | Cardiovascular Nursing | 1 | 2018 | 4 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2020 | 413 | 0.040 |
Why?
| | Drug Combinations | 1 | 2019 | 346 | 0.040 |
Why?
| | Colombia | 1 | 2018 | 41 | 0.040 |
Why?
| | Survivors | 1 | 2022 | 501 | 0.040 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2019 | 147 | 0.040 |
Why?
| | Overweight | 1 | 2023 | 573 | 0.040 |
Why?
| | Fluorouracil | 1 | 2019 | 204 | 0.040 |
Why?
| | Guidelines as Topic | 1 | 2010 | 272 | 0.040 |
Why?
| | Hospitals, Veterans | 1 | 2009 | 255 | 0.030 |
Why?
| | Range of Motion, Articular | 1 | 2020 | 409 | 0.030 |
Why?
| | Biomarkers, Tumor | 1 | 2024 | 1229 | 0.030 |
Why?
| | Chronic Disease | 1 | 2024 | 1804 | 0.030 |
Why?
| | Patient-Centered Care | 1 | 2023 | 546 | 0.030 |
Why?
| | Coinfection | 1 | 2019 | 137 | 0.030 |
Why?
| | Rectum | 1 | 2019 | 188 | 0.030 |
Why?
| | Odds Ratio | 1 | 2010 | 1084 | 0.030 |
Why?
| | Mortality | 1 | 2019 | 360 | 0.030 |
Why?
| | Models, Theoretical | 1 | 2021 | 581 | 0.030 |
Why?
| | Proctitis | 1 | 2016 | 7 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2023 | 1058 | 0.030 |
Why?
| | Viral Load | 1 | 2019 | 495 | 0.030 |
Why?
| | Critical Illness | 1 | 2023 | 836 | 0.030 |
Why?
| | Urogenital System | 1 | 2016 | 17 | 0.030 |
Why?
| | Weight Loss | 1 | 2022 | 783 | 0.030 |
Why?
| | Latin America | 1 | 2016 | 90 | 0.030 |
Why?
| | Mental Health | 1 | 2023 | 742 | 0.030 |
Why?
| | Prisoners | 1 | 2008 | 142 | 0.030 |
Why?
| | Prosthesis Design | 1 | 2018 | 333 | 0.030 |
Why?
| | Sexually Transmitted Diseases | 1 | 2008 | 163 | 0.030 |
Why?
| | Radiotherapy Dosage | 1 | 2016 | 280 | 0.030 |
Why?
| | Population Surveillance | 1 | 2019 | 482 | 0.030 |
Why?
| | Medically Uninsured | 1 | 2017 | 135 | 0.030 |
Why?
| | Anxiety | 1 | 2023 | 1070 | 0.030 |
Why?
| | Health Status | 1 | 2021 | 823 | 0.030 |
Why?
| | Radiation Injuries | 1 | 2016 | 147 | 0.030 |
Why?
| | Self Care | 1 | 2018 | 387 | 0.030 |
Why?
| | Electrocardiography | 1 | 2018 | 610 | 0.030 |
Why?
| | Plant Extracts | 1 | 2016 | 209 | 0.030 |
Why?
| | Curriculum | 1 | 2021 | 1008 | 0.030 |
Why?
| | Public Health | 1 | 2019 | 582 | 0.030 |
Why?
| | Insurance, Health | 1 | 2017 | 297 | 0.030 |
Why?
| | Linear Models | 1 | 2017 | 855 | 0.030 |
Why?
| | Transcription Factors | 1 | 2022 | 1701 | 0.030 |
Why?
| | Administration, Oral | 1 | 2016 | 787 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 897 | 0.030 |
Why?
| | Mutation | 1 | 2025 | 3984 | 0.030 |
Why?
| | Hemorrhage | 1 | 2019 | 747 | 0.030 |
Why?
| | Neoplasms | 1 | 2008 | 2687 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2021 | 3313 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2020 | 3574 | 0.020 |
Why?
| | Sex Factors | 1 | 2018 | 2050 | 0.020 |
Why?
| | Health Promotion | 1 | 2008 | 750 | 0.020 |
Why?
| | Inflammation | 1 | 2022 | 2853 | 0.020 |
Why?
| | Biomarkers | 1 | 2022 | 4095 | 0.020 |
Why?
| | Registries | 1 | 2018 | 2081 | 0.020 |
Why?
| | Obesity | 1 | 2023 | 2994 | 0.020 |
Why?
| | Single-Blind Method | 1 | 2008 | 286 | 0.020 |
Why?
| | Veterans | 1 | 2009 | 1481 | 0.020 |
Why?
| | Health Services Accessibility | 1 | 2009 | 993 | 0.010 |
Why?
|
|
Colborn's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|